Rani Therapeutics Hldgs Financials - Benzinga

Rani Therapeutics Holdings Inc

RANINASDAQ

Trade with Public

Trade with Public

$0.8653

0.01311.54%

At close: Sep 4, 5:00 PM EST

$0.8600

-0.0053-0.61%

After Hours: 6:41 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Rani Therapeutics Hldgs Financials

Rani Therapeutics Hldgs (RANI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 77.78 percent increase over losses of $(0.18) per share

Benzinga Newsdesk

PRO
Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 81.82 percent increase over losses of $(0.22) per share from the same period last

Benzinga Newsdesk

PRO
Rani Therapeutics Hldgs Q4 EPS $(0.07) Misses $(0.06) Estimate, Sales $1.461M Miss $5.000M Estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 22.81 percent. This is a 74.07 percent increase over losses of $(0.27) per

Benzinga Newsdesk

Earnings Scheduled For March 26, 2026

Benzinga Insights

PRO
Rani Therapeutics Hldgs Q3 EPS $(0.12) Beats $(0.15) Estimate

Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, compared to $27.6 million for the year ended December 31, 2024. Rani expects its cash, and cash equivalents, including the

Benzinga Newsdesk

Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings

Avi Kapoor